Dermata Therapeutics Inc (DRMA)vsVertex Pharmaceuticals Inc (VRTX)
DRMA
Dermata Therapeutics Inc
$1.46
-9.32%
HEALTHCARE · Cap: $5.91M
VRTX
Vertex Pharmaceuticals Inc
$547.55
+0.05%
HEALTHCARE · Cap: $130.59B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
DRMA
Avoid23
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DRMA.
Margin of Safety
+43.3%
Fair Value
$966.04
Current Price
$547.55
$418.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DRMA
The strongest argument for DRMA centers on Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : DRMA
The primary concerns for DRMA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
DRMA profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
DRMA carries more volatility with a beta of 0.66 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 23/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Dermata Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead candidate, DMT310. Utilizing a proprietary delivery system, DMT310 seeks to enhance the efficacy of existing acne treatments while addressing significant unmet needs within the dermatology space. With a robust pipeline and a commitment to pioneering dermatological solutions, Dermata Therapeutics is positioned to make a meaningful impact on skin health and improve patient outcomes. As the company advances in its clinical trials, it holds the potential to become a disruptive player in the treatment of skin disorders.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?